Markets for the most part have held up. There are a couple of weak areas. The NQ has lagged both the...
Health Outlook for CVS Caremark
01/28/2014 7:00 am EST
Increased use of generic drugs, along with the rising number of individuals with health insurance, are boosting the long-term prospects for our latest featured stock, a leader in the drugstore and pharmacy benefits sector, notes Richard Moroney, editor of Dow Theory Forecasts.
Analyst earnings estimates have risen since CVS gave its 2014 outlook last month, which implies per-share-profit growth of 10% to 14%. Recent sales gains have been fairly evenly split between the pharmacy-benefit manager (PBM) and drugstore chain.
Wider use of generic drugs—cheaper in price than their branded counterparts, and more profitable for CVS—has helped fatten profit margins.
CVS' pharmacy-benefit manager has exposure to insurance exchanges in 25 states, accounting for almost 70% of the eligible exchange population. PBM growth should contribute to higher foot traffic at CVS retail pharmacies.
The PBM should benefit from expanded coverage offered by the Affordable Care Act, with management expecting 30 million Americans to gain health insurance by 2018.
Other catalysts could help drive long-term growth. Through a venture with Cardinal Health (CAH), CVS will receive a $25 million payment each quarter and gain substantial purchasing power with generic drugs.
Share repurchases should also contribute to the higher per-share profits, with management announcing a fresh $6 billion share-buyback program in December. CVS has lowered its share count 4% in the past year, and by nearly 9% over the last two years.
CVS has raised its dividend, at least 20% in four consecutive years, the most recent, a 22% boost in December. Management expects to return to investors 35% of earnings through dividends by 2018, versus the current payout ratio of about 24%.
To reach that level, CVS estimates it will have to grow the dividend at an annual rate of 18%. Overall, a reasonable valuation, favorable outlook, and strong track record earn CVS a Long-Term Buy rating.
More from MoneyShow.com:
Related Articles on STOCKS
All that need be said trade is that if China retaliates and Trump doubles-down in respect to new tar...
Shares of San Diego-based Kratos Defense & Security Solutions (KTOS) had a rocky start to 2018. ...
My new book, Rule 1 of Investing: How to Always be on the Right Side of the Market, was just release...